The High Court also found Sinopharm Weiqida guilty of Contempt of Court for failing to follow the previously granted preliminary injunction order
ROTTERDAM, the Netherlands, Feb 19 (Bernama-GLOBE NEWSWIRE) --Centrient Pharmaceuticals (“Centrient”), the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals, announced that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceuticals and Sinopharm India, restricting the export and/or import into India of its active pharmaceutical ingredient (API) amoxicillin trihydrate. In addition, the Delhi High Court also found Sinopharm Weiqida prima facie guilty of contempt of Court for illegally importing amoxicillin active ingredients in contravention of the previously granted preliminary injunction in place in India since April 2017. The Court further found that Sinopharm Weiqida has infringed the patent of Centrient.
Centrient, and its wholly owned subsidiaries, Centrient Pharmaceuticals Netherlands B.V. and Centrient Pharmaceuticals India Pvt. Ltd., announced today that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceutical Co., LTD ("Weiqida") blocking the export, importation and sale of its amoxicillin active ingredient into India. The injunction prevents the importation of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India in any form.
Weiqida was also found in contempt of the Delhi High Court’s original preliminary injunction order, granted in April 2017, through its continued importation and sale of its amoxicillin trihydrate active pharmaceutical ingredient in India. Centrient will seek monetary compensation for the damage sustained by the illegal shipments, in violation of the preliminary injunction since April 2017.
Centrient wishes to put all buyers of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India on notice (even if such API transits through India under advanced license) to be aware of the above orders of the Delhi High Court. Centrient shall ensure full compliance of the orders of the Delhi High Court and will notify the Indian Customs Authority and other authorities to seize all future Weiqida amoxicillin shipments at the relevant customs facilities.
Karl Rotthier, CEO at Centrient Pharmaceuticals said: “Centrient holds a world-class intellectual property portfolio relating to our innovative, sustainable and environmentally-friendly amoxicillin technology. We will continue to rigorously defend our Intellectual Property assets worldwide as we continue to invest in our innovative R&D programs directed to enzymatically produced, sustainable antimicrobials and statins. We will continue to supply our customers with reliable, non-infringing, top quality amoxicillin.”
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms. We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines.
With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our 2700 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.
Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (the Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.
For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: alice.beijersbergen@centrient.com
Source : Centrient Pharmaceuticals
--BERNAMA
No comments:
Post a Comment